| scholarly article | Q13442814 |
| P356 | DOI | 10.1124/DMD.109.028498 |
| P698 | PubMed publication ID | 19704027 |
| P50 | author | Katsunobu Hagihara | Q54234768 |
| P2093 | author name string | Nagy A Farid | |
| Osamu Okazaki | |||
| Atsushi Kurihara | |||
| Toshihiko Ikeda | |||
| Miho Kazui | |||
| Michiharu Yoshiike | |||
| Kokichi Honda | |||
| P433 | issue | 11 | |
| P921 | main subject | clopidogrel | Q410237 |
| P304 | page(s) | 2145-2152 | |
| P577 | publication date | 2009-08-24 | |
| P1433 | published in | Drug Metabolism and Disposition | Q1261140 |
| P1476 | title | A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel | |
| P478 | volume | 37 |
| Q47909214 | A Comprehensive Functional Assessment of Carboxylesterase 1 Nonsynonymous Polymorphisms. |
| Q37788682 | A comparison of the metabolism of clopidogrel and prasugrel |
| Q36125455 | A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors |
| Q35750126 | Antiplatelet resistance and thromboembolic complications in neurointerventional procedures. |
| Q47150639 | Arylacetamide Deacetylase Is Involved in Vicagrel Bioactivation in Humans |
| Q38807784 | Arylacetamide Deacetylase is Responsible for Activation of Prasugrel in Human and Dog. |
| Q38132923 | Assessing post-treatment platelet reactivity: a focus on patient selection and setting. |
| Q40734518 | Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. |
| Q53601038 | Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. |
| Q36390258 | Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. |
| Q54053216 | Clarification of the Mechanism of Clopidogrel-Mediated Drug-Drug Interaction in a Clinical Cassette Small-dose Study and Its Prediction Based on In Vitro Information. |
| Q35033722 | Clinical evidence of interaction between clopidogrel and proton pump inhibitors |
| Q57825080 | Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel |
| Q50622756 | Clopidogrel bioactivation and risk of bleeding in patients cotreated with angiotensin-converting enzyme inhibitors after myocardial infarction: a proof-of-concept study |
| Q91867693 | Contribution of Human Liver and Intestinal Carboxylesterases to the Hydrolysis of Selexipag In Vitro |
| Q92355966 | DT-678 inhibits platelet activation with lower tendency for bleeding compared to existing P2Y12 antagonists |
| Q39781068 | Deuterated clopidogrel analogues as a new generation of antiplatelet agents |
| Q43643259 | Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel |
| Q34021173 | Drug interactions and antiretroviral drug monitoring. |
| Q41242987 | Effect of carboxylesterase 1 S75N on clopidogrel therapy among acute coronary syndrome patients |
| Q38243854 | Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures. |
| Q38800092 | Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions-an Industry Perspective |
| Q38131848 | Genetics of platelet inhibitor treatment |
| Q37907918 | Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists |
| Q54979801 | Hypoxia and Ischemia Promote a Maladaptive Platelet Phenotype. |
| Q50591900 | Identifying clinically relevant sources of variability: The clopidogrel challenge |
| Q58555455 | In Vitro Assessment of Potential for CYP-Inhibition-Based Drug-Drug Interaction Between Vonoprazan and Clopidogrel |
| Q30373969 | Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. |
| Q34174915 | Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes |
| Q42731681 | Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases |
| Q30840104 | Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1 |
| Q38071707 | Metabolic differences of current thienopyridine antiplatelet agents |
| Q60017632 | Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients |
| Q34062142 | P2Y nucleotide receptors: promise of therapeutic applications |
| Q26745619 | P2Y12-ADP receptor antagonists: Days of future and past |
| Q38158201 | PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. |
| Q37877165 | Personalized antiplatelet therapy: review of the latest clinical evidence |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q26862694 | Pharmacotherapy in the cardiac catheterization laboratory: evolution and recent developments |
| Q38944892 | Prasugrel suppresses development of lithium-induced nephrogenic diabetes insipidus in mice |
| Q54337089 | Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel. |
| Q38258270 | Resistance to antiplatelet drugs: what progress has been made? |
| Q38048837 | Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors |
| Q36736998 | Sacubitril Is Selectively Activated by Carboxylesterase 1 (CES1) in the Liver and the Activation Is Affected by CES1 Genetic Variation |
| Q41651465 | Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis |
| Q53728226 | Significant Improvement of Metabolic Characteristics and Bioactivities of Clopidogrel and Analogs by Selective Deuteration. |
| Q92594626 | Simultaneous Analysis of Clopidogrel Bisulfate, Acetylsalicylic Acid and Atorvastatin calcium in Tablets by HPLC Method |
| Q37319541 | Species Comparison of Pre-systemic Bioactivation of Vicagrel, a New Acetate Derivative of Clopidogrel |
Search more.